Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc.（GLUE）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · GLUE · 截至 2026年6月8日
活动摘要
买入笔数
1
P-Purchase only
卖出笔数
24
近12个月
买卖比
0.04
Buy/Sell (by trades)
整体情绪
Monte Rosa Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
GLUE 季度内部人买卖趋势
GLUE 内幕交易卖出 · GLUE 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · GLUE CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
GLUE 高管卖出股份 · GLUE 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 1, 2026 | Warmuth Markus President & CEO · Director | Sale | 4,998 | $97K | Form 4 |
| Jun 1, 2026 | Warmuth Markus President & CEO · Director | Sale | 468 | $9K | Form 4 |
| May 29, 2026 | Townson Sharon Chief Scientific Officer | Option | 6,000 | $37K | Form 4 |
| May 29, 2026 | Townson Sharon Chief Scientific Officer | Sale | 6,000 | $119K | Form 4 |
| May 27, 2026 | Champoux Jennifer COO | Option | 2,175 | $9K | Form 4 |
| May 27, 2026 | Champoux Jennifer COO | Sale | 2,175 | $44K | Form 4 |
| May 22, 2026 | Champoux Jennifer COO | Option | 2,176 | $9K | Form 4 |
| May 22, 2026 | Champoux Jennifer COO | Sale | 2,176 | $41K | Form 4 |
| May 21, 2026 | Manning Anthony M. Director | Option | 10,000 | $42K | Form 4 |
| May 21, 2026 | Manning Anthony M. Director | Sale | 10,000 | $180K | Form 4 |
| May 1, 2026 | Warmuth Markus President & CEO · Director | Sale | 5,467 | $103K | Form 4 |
| Apr 14, 2026 | Warmuth Markus President & CEO · Director | Sale | 8,000 | $141K | Form 4 |
| Apr 9, 2026 | Nickson Philip Chief Business & Legal Officer | Sale | 5,845 | $103K | Form 4 |
| Apr 6, 2026 | Bowen Matthew PAO | Award | 4,300 | — | Form 4 |
| Mar 4, 2026 | Dunn Edmund PAO | Sale | 139 | $2K | Form 4 |
| Mar 2, 2026 | Warmuth Markus President & CEO · Director | Sale | 5,466 | $98K | Form 4 |
| Feb 27, 2026 | Dunn Edmund PAO | Option | 25,164 | $337K | Form 4 |
| Mar 2, 2026 | Dunn Edmund PAO | Option | 536 | $7K | Form 4 |
| Mar 2, 2026 | Dunn Edmund PAO | Sale | 536 | $9K | Form 4 |
| Feb 27, 2026 | Dunn Edmund PAO | Sale | 25,164 | $456K | Form 4 |
| Feb 23, 2026 | Janku Filip Chief Medical Officer | Sale | 9,189 | $179K | Form 4 |
| Jan 7, 2026 | Warmuth Markus President & CEO · Director | Sale | 3,707 | $86K | Form 4 |
| Jan 7, 2026 | Warmuth Markus President & CEO · Director | Sale | 1,450 | $35K | Form 4 |
| Jan 7, 2026 | Warmuth Markus President & CEO · Director | Sale | 309 | $8K | Form 4 |
| Jan 2, 2026 | Nickson Philip Chief Business & Legal Officer | Award | 28,000 | — | Form 4 |
Nickson Philip
Chief Business & Legal Officer
日期
Apr 9
股数
5,845
均价
$17.69
总金额
$103K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 GLUE 内幕交易
GLUE 内幕交易
Monte Rosa Therapeutics, Inc.（GLUE）内幕交易数据来源于公司内部人（包括Warmuth Markus (President & CEO · Director), Champoux Jennifer (COO), Dunn Edmund (PAO)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。GLUE内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Monte Rosa Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
GLUE 内幕交易 · 5个问题Monte Rosa Therapeutics, Inc.（GLUE）的内部人包括高管和董事，如Warmuth Markus (President & CEO · Director), Champoux Jennifer (COO), Dunn Edmund (PAO)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026